{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:46:07Z","timestamp":1789962367089,"version":"4.0.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s11906-022-01165-w","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T08:03:33Z","timestamp":1643789013000},"page":"95-106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Refractory Hypertension: a Narrative Systematic Review with Emphasis on Prognosis"],"prefix":"10.1007","volume":"24","author":[{"given":"Giovanna","family":"Bacan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lica","family":"Ribeiro-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius A. S.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia R. L.","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6318-7077","authenticated-orcid":false,"given":"Gil F.","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"1165_CR1","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B, et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich).\u00a02012;14:7\u201312. https:\/\/doi.org\/10.1111\/j.1751-7176.2011.00556.x. The first description of refractory hypertension (RfHT).","DOI":"10.1111\/j.1751-7176.2011.00556.x"},{"key":"1165_CR2","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Calhoun DA, Booth JN 3rd, Oparil S, Irvin MR, Shimbo D, Lackland DT, et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension.\u00a02014;63:451\u20138.\u00a0https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.02026. One of the largest studies describing prevalence and clinical features of RfHT.","DOI":"10.1161\/HYPERTENSIONAHA.113.02026"},{"key":"1165_CR3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jash.2015.03.005","volume":"9","author":"R Modolo","year":"2015","unstructured":"Modolo R, de Faria AP, Sabbatini AR, Barbaro NR, Ritter AM, Moreno H. Refractory and resistant hypertension: characteristics and differences observed in a specialized clinic. J Am Soc Hypertens. 2015;9:397\u2013402. https:\/\/doi.org\/10.1016\/j.jash.2015.03.005.","journal-title":"J Am Soc Hypertens"},{"key":"1165_CR4","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure. Hypertension.\u00a02015;66:126\u201333.\u00a0https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.115.05449. The study that provided most of the evidences favoring a neurogenic physiopathological basis for RfHT.","DOI":"10.1161\/HYPERTENSIONAHA.115.05449"},{"key":"1165_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1161\/HYPERTENSIONAHA.117.09464","volume":"70","author":"M Siddiqui","year":"2017","unstructured":"Siddiqui M, Judd EK, Oparil S, Calhoun DA. White-coat effect is uncommon in patients with refractory hypertension. Hypertension. 2017;70:645\u201351. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.09464.","journal-title":"Hypertension"},{"key":"1165_CR6","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Armario P, Calhoun DA, Oliveras A, Blanch P, Vinyoles E, Banegas JR, et al. Prevalence and clinical characteristics of refractory hypertension. J Am Heart Assoc.\u00a02017;6:e007365.\u00a0https:\/\/doi.org\/10.1161\/JAHA.117.007365. The largest study that evaluated prevalence, clinical features and white-coat effect in RfHT.","DOI":"10.1161\/JAHA.117.007365"},{"key":"1165_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/00325481.2017.1272398","volume":"129","author":"G Cao","year":"2017","unstructured":"Cao G, Chen C, Lin Q, Chen Y, Zhen Z, Zou Y, et al. Prevalence, clinical characteristics and echocardiography parameters of non-resistant, resistant and refractory hypertension in Chinese. Postgrad Med. 2017;129:187\u201392. https:\/\/doi.org\/10.1080\/00325481.2017.1272398.","journal-title":"Postgrad Med"},{"key":"1165_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1161\/HYPERTENSIONAHA.118.10965","volume":"72","author":"A Velasco","year":"2018","unstructured":"Velasco A, Siddiqui M, Kreps E, Kolakalapudi P, Dudenbostel T, Arora G, et al. Refractory hypertension is not attributable to intravascular fluid retention as determined by intracardiac volumes. Hypertension. 2018;72:343\u20139. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.10965.","journal-title":"Hypertension"},{"key":"1165_CR9","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.118.11170","volume":"72","author":"MA Mart\u00ednez-Garc\u00eda","year":"2018","unstructured":"Mart\u00ednez-Garc\u00eda MA, Navarro-Soriano C, Torres G, Barb\u00e9 F, Caballero-Eraso C, Lloberes P, et al. on behalf the Spanish Sleep Network. Beyond resistant hypertension Hypertension. 2018;72:618\u201324. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11170.","journal-title":"Beyond resistant hypertension Hypertension"},{"key":"1165_CR10","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Buhnerkempe MG, Botchway A, Prakash V, Al-Akchar M, Nolasco Morales CE, et al. Prevalence of refractory hypertension in the United States from 1999 to 2014. J Hypertens.\u00a02019;37:1797\u2013804.\u00a0https:\/\/doi.org\/10.1097\/HJH.0000000000002103. A comprehensive analysis of the prevalence of RfHT in the US population.","DOI":"10.1097\/HJH.0000000000002103"},{"key":"1165_CR11","doi-asserted-by":"crossref","unstructured":"Sharma V, Gupta P, Strauch B, Wu S, Ali-Abdulnabi M, Tarapuri S, Widimsky J, Patel P, Tomaszewski M. Refractory versus resistant hypertension: is it related excess sympathetic activity? J Am Coll Cardiol.\u00a02019;73(9):1817 [abstract].","DOI":"10.1016\/S0735-1097(19)32423-4"},{"key":"1165_CR12","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1097\/HJH.0000000000002441","volume":"38","author":"M Parasiliti-Caprino","year":"2020","unstructured":"Parasiliti-Caprino M, Lopez C, Prencipe N, Lucatello B, Settanni F, Giraudo G, et al. Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension. J Hypertens. 2020;38:1841\u20138. https:\/\/doi.org\/10.1097\/HJH.0000000000002441.","journal-title":"J Hypertens"},{"key":"1165_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116976","volume":"415","author":"FS Sarfo","year":"2020","unstructured":"Sarfo FS, Akassi J, Adamu S, Obese V, Agbenorku M, Ovbiagele B. Frequency and factors linked to refractory hypertension among stroke survivors in Ghana. J Neurol Sci. 2020;415: 116976. https:\/\/doi.org\/10.1016\/j.jns.2020.116976.","journal-title":"J Neurol Sci"},{"key":"1165_CR14","doi-asserted-by":"publisher","unstructured":"Macedo C, Aras Junior R, Macedo IS. Clinical characteristics of resistant vs. refractory hypertension in a population of hypertensive Afrodescendants. Arq Bras Cardiol.\u00a02020;115:31\u20139.\u00a0https:\/\/doi.org\/10.36660\/abc.20190218.","DOI":"10.36660\/abc.20190218"},{"key":"1165_CR15","doi-asserted-by":"publisher","unstructured":"Chedier B, Cortez AF, Roderjan CN, Cavalcanti AH, Carlos FOC, Dos Santos BDM, Muxfeldt ES. Prevalence and clinical profile of refractory hypertension in a large cohort of patients with resistant hypertension. J Hum Hypertens.\u00a02020.\u00a0https:\/\/doi.org\/10.1038\/s41371-020-00406-2. Epub ahead of print.","DOI":"10.1038\/s41371-020-00406-2"},{"key":"1165_CR16","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Siddiqui M, Judd EK, Dudenbostel T, Gupta P, Tomaszewski M, Patel P, Oparil S, Calhoun DA. Antihypertensive medication adherence and confirmation of true refractory hypertension. Hypertension.\u00a02020;75:510\u20135.\u00a0https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.14137. The only study that evaluated drug treatment adherence in RfHT.","DOI":"10.1161\/HYPERTENSIONAHA.119.14137"},{"key":"1165_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.26442\/00403660.2021.01.200593","volume":"93","author":"AY Falkovskaya","year":"2021","unstructured":"Falkovskaya AY, Mordovin VF, Pekarskiy SE, Ripp TM, Manukyan MA, Lichikaki VA, et al. Refractory and resistant hypertension in patients with type 2 diabetes mellitus: differences in metabolic profile and endothelial function. Ter Arkh. 2021;93:49\u201358. https:\/\/doi.org\/10.26442\/00403660.2021.01.200593.","journal-title":"Ter Arkh"},{"key":"1165_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/HJH.0000000000002631","volume":"39","author":"SJ Thomas","year":"2021","unstructured":"Thomas SJ, Siddiqui M, Judd E, Moore D, Harding SM, Oparil S, Calhoun D. Obstructive sleep apnea is more severe in men but not women with refractory hypertension compared with controlled resistant hypertension. J Hypertens. 2021;39:286\u201391. https:\/\/doi.org\/10.1097\/HJH.0000000000002631.","journal-title":"J Hypertens"},{"key":"1165_CR19","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Navarro-Soriano C, Mart\u00ednez-Garc\u00eda MA, Torres G, Barb\u00e9 F, Caballero-Eraso C, Lloberes P, et al. Spanish Sleep Network. Factors associated with the changes from a resistant to a refractory phenotype in hypertensive patients: a pragmatic longitudinal study. Hypertens Res.\u00a02019;42:1708\u201315.\u00a0https:\/\/doi.org\/10.1038\/s41440-019-0285-8. The first study that evaluated factors associated with progression from resistant to refractory hypertension.","DOI":"10.1038\/s41440-019-0285-8"},{"key":"1165_CR20","doi-asserted-by":"publisher","unstructured":"Navarro-Soriano C, Mart\u00ednez-Garc\u00eda MA, Torres G, Barb\u00e9 F, Caballero-Eraso C, Lloberes P, et al; on behalf the Spanish Sleep Network. Effect of continuous positive airway pressure in patients with true refractory hypertension and sleep apnea: a post-hoc intention-to-treat analysis of the HIPARCO randomized clinical trial. J Hypertens.\u00a02019;37:1269\u201375.\u00a0https:\/\/doi.org\/10.1097\/HJH.0000000000002053.","DOI":"10.1097\/HJH.0000000000002053"},{"key":"1165_CR21","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/ajh\/hpaa042","volume":"33","author":"M Siddiqui","year":"2020","unstructured":"Siddiqui M, Bhatt H, Judd EK, Oparil S, Calhoun DA. Reserpine substantially lowers blood pressure in patients with refractory hypertension: a proof-of-concept study. Am J Hypertens. 2020;33:741\u20137. https:\/\/doi.org\/10.1093\/ajh\/hpaa042.","journal-title":"Am J Hypertens"},{"key":"1165_CR22","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Cardoso CRL, Salles GF. Refractory hypertension and risks of adverse cardiovascular events and mortality in patients with resistant hypertension: a\u00a0prospective cohort study. J Am Heart Assoc.\u00a02020;9:e017634.\u00a0https:\/\/doi.org\/10.1161\/JAHA.120.017634. The first study that evaluated the prognosis of RfHT in relation to resistant hypertension (RHT).","DOI":"10.1161\/JAHA.120.017634"},{"key":"1165_CR23","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Buhnerkempe MG, Prakash V, Botchway A, Adekola B, Cohen JB, Rahman M, et al. Adverse health outcomes associated with refractory and treatment-resistant hypertension in the Chronic Renal Insufficiency Cohort. Hypertension.\u00a02021;77:72\u201381.\u00a0https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15064. The second study that evaluated the prognosis of RfHT, the first in CKD patients.","DOI":"10.1161\/HYPERTENSIONAHA.120.15064"},{"key":"1165_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.18087\/cardio.2021.2.n1102","volume":"61","author":"AY Falkovskaya","year":"2021","unstructured":"Falkovskaya AY, Mordovin VF, Pekarskiy SE, Manukyan MA, Ripp TM, Zyubanova IV, et al. Refractory and resistant hypertension in patients with type 2 diabetes mellitus: different response to renal denervation. Kardiologiia. 2021;61:54\u201361. https:\/\/doi.org\/10.18087\/cardio.2021.2.n1102.","journal-title":"Kardiologiia"},{"key":"1165_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11906-014-0485-1","volume":"16","author":"R Modolo","year":"2014","unstructured":"Modolo R, de Faria AP, Almeida A, Moreno H. Resistant or refractory hypertension: are they different? Curr Hypertens Rep. 2014;16:485. https:\/\/doi.org\/10.1007\/s11906-014-0485-1.","journal-title":"Curr Hypertens Rep"},{"key":"1165_CR26","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA. Refractory hypertension: a novel phenotype of antihypertensive treatment failure. Hypertension.\u00a02016;67:1085\u201392.\u00a0https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.06587. The first proposal to include the obligatory use of a long-acting thiazide (or thiazide-like) diuretic and a mineraloreceptor antagonist into the definition of RfHT.","DOI":"10.1161\/HYPERTENSIONAHA.116.06587"},{"key":"1165_CR27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cjca.2015.06.033","volume":"32","author":"M Siddiqui","year":"2016","unstructured":"Siddiqui M, Dudenbostel T, Calhoun DA. Resistant and refractory hypertension: antihypertensive treatment resistance vs treatment failure. Can J Cardiol. 2016;32:603\u20136. https:\/\/doi.org\/10.1016\/j.cjca.2015.06.033.","journal-title":"Can J Cardiol"},{"key":"1165_CR28","doi-asserted-by":"publisher","first-page":"593","DOI":"10.4070\/kcj.2016.46.5.593","volume":"46","author":"DA Calhoun","year":"2016","unstructured":"Calhoun DA. Refractory and resistant hypertension: antihypertensive treatment failure versus treatment resistance. Korean Circ J. 2016;46:593\u2013600. https:\/\/doi.org\/10.4070\/kcj.2016.46.5.593.","journal-title":"Korean Circ J"},{"key":"1165_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11906-017-0713-6","volume":"19","author":"TH Le Jemtel","year":"2017","unstructured":"Le Jemtel TH, Richardson W, Samson R, Jaiswal A, Oparil S. Pathophysiology and potential non-pharmacologic treatments of obesity or kidney disease associated refractory hypertension. Curr Hypertens Rep. 2017;19:18. https:\/\/doi.org\/10.1007\/s11906-017-0713-6.","journal-title":"Curr Hypertens Rep"},{"key":"1165_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/MNH.0000000000000286","volume":"26","author":"M Siddiqui","year":"2017","unstructured":"Siddiqui M, Calhoun DA. Refractory versus resistant hypertension. Curr Opin Nephrol Hypertens. 2017;26:14\u20139. https:\/\/doi.org\/10.1097\/MNH.0000000000000286.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1165_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1161\/HYPERTENSIONAHA.117.08929","volume":"70","author":"A Cai","year":"2017","unstructured":"Cai A, Calhoun DA. Resistant hypertension: an update of experimental and clinical findings. Hypertension. 2017;70:5\u20139. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.08929.","journal-title":"Hypertension"},{"key":"1165_CR32","unstructured":"Dudenbostel T, Siddiqui M, Gharpure N, Calhoun DA. Refractory versus resistant hypertension: novel distinctive phenotypes. J Nat Sci.\u00a02017;3:e430. PMID: 29034321; PMCID: PMC5640321."},{"key":"1165_CR33","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1590\/2175-8239-jbn-2018-0108","volume":"41","author":"ES Muxfeldt","year":"2019","unstructured":"Muxfeldt ES, Chedier B, Rodrigues CIS. Resistant and refractory hypertension: two sides of the same disease? J Bras Nefrol. 2019;41:266\u201374. https:\/\/doi.org\/10.1590\/2175-8239-jbn-2018-0108.","journal-title":"J Bras Nefrol"},{"key":"1165_CR34","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1161\/CIRCRESAHA.118.312156","volume":"124","author":"MC Acelajado","year":"2019","unstructured":"Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of resistant and refractory hypertension. Circ Res. 2019;124:1061\u201370. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.312156.","journal-title":"Circ Res"},{"key":"1165_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11906-019-0963-6","volume":"21","author":"G Oscullo","year":"2019","unstructured":"Oscullo G, Sapi\u00f1a-Beltr\u00e1n E, Torres G, Zaldivar E, Barb\u00e9 F, Martinez-Garcia MA. The potential role of obstructive sleep apnoea in refractory hypertension. Curr Hypertens Rep. 2019;21:57. https:\/\/doi.org\/10.1007\/s11906-019-0963-6.","journal-title":"Curr Hypertens Rep"},{"key":"1165_CR36","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/ehjcvp\/pvz057","volume":"6","author":"LM Ruilope","year":"2020","unstructured":"Ruilope LM, Rodr\u00edguez-S\u00e1nchez E, Navarro-Garc\u00eda JA, Segura J, \u00d3rtiz A, Lucia A, Ruiz-Hurtado G. Resistant hypertension: new insights and therapeutic perspectives. Eur Heart J Cardiovasc Pharmacother. 2020;6:188\u201393. https:\/\/doi.org\/10.1093\/ehjcvp\/pvz057.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"1165_CR37","doi-asserted-by":"publisher","unstructured":"Doumas M, Imprialos KP, Kallistratos MS, Manolis AJ. Recent advances in understanding and managing resistant\/refractory hypertension. F1000Res.\u00a02020;9:F1000 Faculty Rev-169.\u00a0https:\/\/doi.org\/10.12688\/f1000research.21669.1.","DOI":"10.12688\/f1000research.21669.1"},{"key":"1165_CR38","doi-asserted-by":"publisher","unstructured":"Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension.\u00a02008;51:1403\u201319.\u00a0https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.108.189141.","DOI":"10.1161\/HYPERTENSIONAHA.108.189141"},{"key":"1165_CR39","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/jamainternmed.2019.7454","volume":"180","author":"G Hripcsak","year":"2020","unstructured":"Hripcsak G, Suchard MA, Shea S, Chen R, You SC, Pratt N, et al. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med. 2020;180:542\u201351. https:\/\/doi.org\/10.1001\/jamainternmed.2019.7454.","journal-title":"JAMA Intern Med"},{"key":"1165_CR40","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/MBP.0000000000000486","volume":"26","author":"S Dineva","year":"2021","unstructured":"Dineva S, Uzunova K, Pavlova V, Filipova E, Kalinov K, Vekov T. Network meta-analysis of efficacy and safety of chlorthalidone and hydrochlorothiazide in hypertensive patients. Blood Press Monit. 2021;26:160\u20138. https:\/\/doi.org\/10.1097\/MBP.0000000000000486.","journal-title":"Blood Press Monit"},{"key":"1165_CR41","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1097\/HJH.0000000000002771","volume":"39","author":"GC Roush","year":"2021","unstructured":"Roush GC, Messerli FH. Chlorthalidone versus hydrochlorothiazide: major cardiovascular events, blood pressure, left ventricular mass, and adverse effects. J Hypertens. 2021;39:1254\u201360. https:\/\/doi.org\/10.1097\/HJH.0000000000002771.","journal-title":"J Hypertens"},{"key":"1165_CR42","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/j.jacc.2017.11.005","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/ NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:2199\u2013269. https:\/\/doi.org\/10.1016\/j.jacc.2017.11.005.","journal-title":"J Am Coll Cardiol"},{"key":"1165_CR43","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/S0140-6736(17)32136-0","volume":"390","author":"A Agust\u00ed","year":"2017","unstructured":"Agust\u00ed A, Celli B, Faner R. What does endotyping mean for treatment in chronic obstructive pulmonary disease? Lancet. 2017;390:980\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(17)32136-0.","journal-title":"Lancet"},{"key":"1165_CR44","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","volume":"168","author":"KK Gaddam","year":"2008","unstructured":"Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168:1159\u201364. https:\/\/doi.org\/10.1001\/archinte.168.11.1159.","journal-title":"Arch Intern Med"},{"key":"1165_CR45","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1161\/01.hyp.0000040261.30455.b6","volume":"40","author":"DA Calhoun","year":"2002","unstructured":"Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892\u20136. https:\/\/doi.org\/10.1161\/01.hyp.0000040261.30455.b6.","journal-title":"Hypertension"},{"key":"1165_CR46","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1161\/HYPERTENSIONAHA.109.131235","volume":"54","author":"E Pimenta","year":"2009","unstructured":"Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell\u2019Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54:475\u201381. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.131235.","journal-title":"Hypertension"},{"key":"1165_CR47","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","volume":"22","author":"IK Eide","year":"2004","unstructured":"Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22:2217\u201326. https:\/\/doi.org\/10.1097\/00004872-200411000-00026.","journal-title":"J Hypertens"},{"key":"1165_CR48","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","volume":"55","author":"F de Souza","year":"2010","unstructured":"de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;55:147\u201352. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.140988.","journal-title":"Hypertension"},{"key":"1165_CR49","doi-asserted-by":"publisher","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet.\u00a02015;386:2059\u201368.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(15)00257-3.","DOI":"10.1016\/S0140-6736(15)00257-3"},{"key":"1165_CR50","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jacc.2016.11.069","volume":"69","author":"S Javaheri","year":"2017","unstructured":"Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S, et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol. 2017;69:841\u201358. https:\/\/doi.org\/10.1016\/j.jacc.2016.11.069.","journal-title":"J Am Coll Cardiol"},{"key":"1165_CR51","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/HJH.0b013e32835e2286","volume":"31","author":"O Jung","year":"2013","unstructured":"Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31:766\u201374. https:\/\/doi.org\/10.1097\/HJH.0b013e32835e2286.","journal-title":"J Hypertens"},{"key":"1165_CR52","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1136\/heartjnl-2013-305063","volume":"100","author":"M Tomaszewski","year":"2014","unstructured":"Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS\/MS) urine analysis. Heart. 2014;100:855\u201361. https:\/\/doi.org\/10.1136\/heartjnl-2013-305063.","journal-title":"Heart"},{"key":"1165_CR53","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00126097-200310000-00001","volume":"8","author":"ES Muxfeldt","year":"2003","unstructured":"Muxfeldt ES, Bloch KV, Nogueira AR, Salles GF. Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension. Blood Press Monit. 2003;8:181\u20135. https:\/\/doi.org\/10.1097\/00126097-200310000-00001.","journal-title":"Blood Press Monit"},{"key":"1165_CR54","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","volume":"57","author":"A de la Sierra","year":"2011","unstructured":"de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898\u2013902. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.168948.","journal-title":"Hypertension"},{"key":"1165_CR55","doi-asserted-by":"publisher","unstructured":"Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. American Heart Association Professional\/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension.\u00a02018;72:e53\u2013e90.\u00a0https:\/\/doi.org\/10.1161\/HYP.0000000000000084.","DOI":"10.1161\/HYP.0000000000000084"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-022-01165-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-022-01165-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-022-01165-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T13:50:37Z","timestamp":1648561837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-022-01165-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1165"],"URL":"https:\/\/doi.org\/10.1007\/s11906-022-01165-w","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"9 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}